Notch1 Signaling Sensitizes Tumor Necrosis Factor-related Apoptosis-inducing Ligand-induced Apoptosis in Human Hepatocellular Carcinoma Cells by Inhibiting Akt/Hdm2-mediated P53 Degradation and Up-regulating P53-dependent DR5 Expression

Overview

Journal J Biol Chem

Specialty Biochemistry

Date 2009 Apr 21

PMID 19376776

Citations 45

Authors

Chunmei Wang

Runzi Qi

Nan Li

Zhengxin Wang

Huazhang An

Qinghua Zhang

Yizhi Yu

Xuetao Cao

Affiliations

Soon will be listed here.

Abstract

Notch signaling plays a critical role in regulating cell proliferation, differentiation, and apoptosis. Our previous study showed that overexpression of Notch1 could inhibit human hepatocellular carcinoma (HCC) cell growth by arresting the cell cycle and inducing apoptosis. HCC cells are resistant to apoptotic induction by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), so new therapeutic approaches have been explored to sensitize HCC cells to TRAIL-induced apoptosis. We are wondering whether and how Notch1 signaling can enhance the sensitivity of HCC cells to TRAIL-induced apoptosis. In this study, we found that overexpression of ICN, the constitutive activated form of Notch1, up-regulated p53 protein expression in HCC cells by inhibiting proteasome degradation. p53 up-regulation was further observed in human primary hepatocellular carcinoma cells after activation of Notch signaling. Inhibition of the Akt/Hdm2 pathway by Notch1 signaling was responsible for the suppression of p53 proteasomal degradation, thus contributing to the Notch1 signaling-mediated up-regulation of p53 expression. Accordingly, Notch1 signaling could make HCC cells more sensitive to TRAIL-induced apoptosis, whereas Notch1 signaling lost the synergistic promotion of TRAIL-induced apoptosis in p53-silenced HepG2 HCC cells and p53-defective Hep3B HCC cells. The data suggest that enhancement of TRAIL-induced apoptosis by Notch1 signaling is dependent upon p53 up-regulation. Furthermore, Notch1 signaling could enhance DR5 expression in a p53-dependent manner. Taken together, Notch1 signaling sensitizes TRAIL-induced apoptosis in HCC cells by inhibiting Akt/Hdm2-mediated p53 degradation and up-regulating p53-dependent DR5 expression. Thus, our results suggest that activation of Notch1 signaling may be a promising approach to improve the therapeutic efficacy of TRAIL-resistant HCC.

Citing Articles

What is the role of Von Willebrand factor in chronic hepatitis B virus infection to hepatocellular carcinoma: a review article.

Xiang Q, Tao J, Li J, Tian R, Li X Ther Adv Chronic Dis. 2022; 13:20406223221125683.

PMID: 36407018 PMC: 9669690. DOI: 10.1177/20406223221125683.

Targeting Notch to Maximize Chemotherapeutic Benefits: Rationale, Advanced Strategies, and Future Perspectives.

Zhdanovskaya N, Firrincieli M, Lazzari S, Pace E, Scribani Rossi P, Felli M Cancers (Basel). 2021; 13(20).

PMID: 34680255 PMC: 8533696. DOI: 10.3390/cancers13205106.

Hypermethylation of GNA14 and its tumor-suppressive role in hepatitis B virus-related hepatocellular carcinoma.

Song G, Zhu X, Xuan Z, Zhao L, Dong H, Chen J Theranostics. 2021; 11(5):2318-2333.

PMID: 33500727 PMC: 7797690. DOI: 10.7150/thno.48739.

Alagille syndrome and risk for hepatocellular carcinoma: Need for increased surveillance in adults with mild liver phenotypes.

Schindler E, Gilbert M, Piccoli D, Spinner N, Krantz I, Loomes K Am J Med Genet A. 2020; 185(3):719-731.

PMID: 33369123 PMC: 7898517. DOI: 10.1002/ajmg.a.62028.

The Carcinogenic Role of the Notch Signaling Pathway in the Development of Hepatocellular Carcinoma.

Huang Q, Li J, Zheng J, Wei A J Cancer. 2019; 10(6):1570-1579.

PMID: 31031867 PMC: 6485212. DOI: 10.7150/jca.26847.

References

Ganten T, Haas T, Sykora J, Stahl H, Sprick M, Fas S . Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death Differ. 2004; 11 Suppl 1:S86-96. DOI: 10.1038/sj.cdd.4401437. View

Yang X, Klein R, Tian X, Cheng H, Kopan R, Shen J . Notch activation induces apoptosis in neural progenitor cells through a p53-dependent pathway. Dev Biol. 2004; 269(1):81-94. DOI: 10.1016/j.ydbio.2004.01.014. View

Shigeno M, Nakao K, Ichikawa T, Suzuki K, Kawakami A, Abiru S . Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kappa B inactivation. Oncogene. 2003; 22(11):1653-62. DOI: 10.1038/sj.onc.1206139. View

Ichikawa K, Liu W, Zhao L, Wang Z, Liu D, Ohtsuka T . Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med. 2001; 7(8):954-60. DOI: 10.1038/91000. View

Walker L, Browning D, Miyamoto A, Weinmaster G, Gasson J . Notch signaling enhances survival and alters differentiation of 32D myeloblasts. J Immunol. 2000; 165(8):4428-36. DOI: 10.4049/jimmunol.165.8.4428. View

Liu X, Yao M, Li N, Wang C, Zheng Y, Cao X . CaMKII promotes TLR-triggered proinflammatory cytokine and type I interferon production by directly binding and activating TAK1 and IRF3 in macrophages. Blood. 2008; 112(13):4961-70. DOI: 10.1182/blood-2008-03-144022. View

Zhou J, Lu G, Ong C, Ong C, Shen H . Andrographolide sensitizes cancer cells to TRAIL-induced apoptosis via p53-mediated death receptor 4 up-regulation. Mol Cancer Ther. 2008; 7(7):2170-80. DOI: 10.1158/1535-7163.MCT-08-0071. View

Lavin M, Gueven N . The complexity of p53 stabilization and activation. Cell Death Differ. 2006; 13(6):941-50. DOI: 10.1038/sj.cdd.4401925. View

Zhou B, Liao Y, Xia W, Zou Y, Spohn B, Hung M . HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol. 2001; 3(11):973-82. DOI: 10.1038/ncb1101-973. View

10.

Oikonomou E, Kothonidis K, Taoufik E, Probert E, Zografos G, Nasioulas G . Newly established tumourigenic primary human colon cancer cell lines are sensitive to TRAIL-induced apoptosis in vitro and in vivo. Br J Cancer. 2007; 97(1):73-84. PMC: 2359667. DOI: 10.1038/sj.bjc.6603835. View

11.

Sriuranpong V, Borges M, Ravi R, Arnold D, Nelkin B, Baylin S . Notch signaling induces cell cycle arrest in small cell lung cancer cells. Cancer Res. 2001; 61(7):3200-5. View

12.

Yagita H, Takeda K, Hayakawa Y, Smyth M, Okumura K . TRAIL and its receptors as targets for cancer therapy. Cancer Sci. 2004; 95(10):777-83. PMC: 11159975. DOI: 10.1111/j.1349-7006.2004.tb02181.x. View

13.

Meng R, El-Deiry W . p53-independent upregulation of KILLER/DR5 TRAIL receptor expression by glucocorticoids and interferon-gamma. Exp Cell Res. 2001; 262(2):154-69. DOI: 10.1006/excr.2000.5073. View

14.

Kelley S, Ashkenazi A . Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol. 2004; 4(4):333-9. DOI: 10.1016/j.coph.2004.02.006. View

15.

Armeanu S, Lauer U, Smirnow I, Schenk M, Weiss T, Gregor M . Adenoviral gene transfer of tumor necrosis factor-related apoptosis-inducing ligand overcomes an impaired response of hepatoma cells but causes severe apoptosis in primary human hepatocytes. Cancer Res. 2003; 63(10):2369-72. View

16.

LeBlanc H, Ashkenazi A . Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ. 2003; 10(1):66-75. DOI: 10.1038/sj.cdd.4401187. View

17.

Yoeli-Lerner M, Yiu G, Rabinovitz I, Erhardt P, Jauliac S, Toker A . Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT. Mol Cell. 2005; 20(4):539-50. DOI: 10.1016/j.molcel.2005.10.033. View

18.

Takimoto R, El-Deiry W . Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene. 2000; 19(14):1735-43. DOI: 10.1038/sj.onc.1203489. View

19.

Carter B, Mak D, Schober W, Dietrich M, Pinilla C, Vassilev L . Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5. Blood. 2008; 111(7):3742-50. PMC: 2275030. DOI: 10.1182/blood-2007-05-091504. View

20.

Huang J, Wu L, Tashiro S, Onodera S, Ikejima T . Reactive oxygen species mediate oridonin-induced HepG2 apoptosis through p53, MAPK, and mitochondrial signaling pathways. J Pharmacol Sci. 2008; 107(4):370-9. DOI: 10.1254/jphs.08044fp. View